Does the IRS1-region variant rs2943641 reduce insulin sensitivity and increase type 2 diabetes risk?

The IRS1-region variant rs2943641 is a well-characterized genetic locus significantly associated with metabolic health outcomes, specifically insulin resistance and type 2 diabetes (T2D) risk.

Clinical and effectiveness evidence

Large-scale genome-wide association studies (GWAS) and meta-analyses consistently link the rs2943641-C allele to markers of impaired metabolic function.

• Insulin Sensitivity: Evidence from hyperinsulinemic-euglycemic clamp studies—the gold standard for measuring insulin action—shows that the risk allele is associated with lower glucose disposal rates. Surrogate measures, such as the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), further demonstrate increased insulin resistance in carriers of the rs2943641-C allele.
• Type 2 Diabetes Risk: Meta-analyses of large cohorts, including UK populations, have confirmed that this variant is a significant locus for T2D susceptibility. Carriers of the protective T-allele have an approximately 6–11% lower risk of developing T2D compared to those with the CC genotype (OR 0.89; 95% CI: 0.80–1.00), validating the C-allele as a risk factor for the disease.
• Sex-Specific Effects: Some research suggests that the metabolic impact of this variant may be more pronounced in women, making it particularly relevant for female patients in middle age.

Mechanistic explanations

The IRS1 (Insulin Receptor Substrate 1) protein is a fundamental adaptor molecule in the insulin signaling cascade.

• Signaling Pathway: Under normal conditions, insulin binding triggers the tyrosine phosphorylation of IRS1, which recruits phosphoinositide 3-kinase (PI3K). This activates the AKT pathway, driving the translocation of GLUT4 transporters to the cell membrane for glucose uptake.
• Genetic Influence: While rs2943641 is located in a non-coding region, it is believed to influence the expression or function of the IRS1 protein, particularly within adipose tissue. The risk-conferring variant disrupts this downstream PI3K-AKT signaling, leading to diminished peripheral insulin action and systemic resistance.

Bottom line

The rs2943641-C variant is a validated risk factor for type 2 diabetes and reduced insulin sensitivity. It operates by impairing the IRS1-mediated signaling pathway, a core mechanism of glucose regulation, and may have heightened significance in female populations.